Patents Assigned to AstraZeneca AB
  • Tetracyclic heteroaryl compounds
    Patent number: 11407765
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca, AB
    Inventors: Jason Grant Kettle, Sharanjeet Kaur Bagal, Andrew John Eatherton, Shaun Michael Fillery, Graeme Richard Robb, Scott Gibson Lamont, Paul David Kemmitt, Frederick Woolf Goldberg
  • METHODS OF USING LIPID NANOPARTICLES FOR DELIVERING MODIFIED RNA ENCODING A VEGF-A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20220226243
    Abstract: The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject. Some aspects of the disclosure relate to the topical administration of nanoparticles comprising a lipid component and a modified RNA.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 21, 2022
    Applicant: AstraZeneca AB
    Inventors: Kenny Mikael Hansson, Maria Wågberg, Nils Bergenhem
  • COMPOSITIONS FOR SKIN AND WOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220226438
    Abstract: This disclosure relates to mRNA therapy for (i) the promotion and/or improvement of wound healing, (ii) the prevention and/or reduction of scar formation at a wound, (iii) the reduction of the visibility of a scar, and/or (iv) the treatment of epidermolysis bullosa. mRNAs for use in the invention, when intradermally (e.g., using microneedles) or topically administered in vivo, encode a wound healing polypeptide (e.g., a growth factor, a cytokine, a chemokine, a protease inhibitor, or a collagen).
    Type: Application
    Filed: May 8, 2020
    Publication date: July 21, 2022
    Applicant: AstraZeneca AB
    Inventors: Kenny Mikael Hansson, Maria Wågberg, Nils Bergenhem
  • Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
    Patent number: 11382951
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: July 12, 2022
    Assignees: Pieris Pharmaceuticals GmbH, AstraZeneca AB
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Medicament dispensing system and dispensing method
    Patent number: 11382836
    Abstract: A dispensing system (2) and method for dispensing unit dosage forms (38) from a blister pack (30) is disclosed. The system (2) comprises a housing (4) for receiving a blister pack (30), the blister pack (30) having a plurality of cavities (32) with at least one unit dosage form (38) sealed in each of the cavities (32), the housing (4) comprising at least one housing aperture. The system (2) also comprises a sensing layer comprising a plurality of apertures, each sensing layer aperture configured to substantially align with a corresponding one or more of the plurality of cavities (32) of the blister pack (30) when a blister pack (30) is received in the housing (4) and at least one sensing region. The system (2) further comprises an electronics unit and a power source for providing voltage to the sensing layer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: July 12, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Fredrik Jonsson, Lubomir Gradinarsky
  • Pyridine and pyrimidine derivatives
    Patent number: 11352369
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Chemical compounds
    Patent number: 11325906
    Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 10, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Sebastien Louis Degorce, Martin John Packer
  • Composition for inhalation
    Patent number: 11311558
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Gene modification assays
    Patent number: 11254928
    Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 22, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Amir Taheri-Ghahfarokhi, Mohammad Bohlooly-Yeganeh, Lorenz M. Mayr
  • PCSK9 inhibitors and methods of use thereof
    Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Protein kinase B inhibitors
    Patent number: 11236095
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 1, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof
    Patent number: 11180477
    Abstract: An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 23, 2021
    Assignee: AstraZeneca AB
    Inventors: Alistair John Boyd, Alexander Telford
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20210355127
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: April 22, 2021
    Publication date: November 18, 2021
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof Broddefalk, Hans Fredrik Emtenäs, Kenneth Lars Granberg, Malin Anita Lemurell, Daniel Tor Pettersen, Alleyn Thomas Plowright, Lars Johan Andreas Ulander
  • METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB
    Publication number: 20210322415
    Abstract: Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy.
    Type: Application
    Filed: February 14, 2017
    Publication date: October 21, 2021
    Applicants: ASTRAZENECA AB, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Simon BARRY, Jane KENDREW, Tony HO, Stephen Robert WEDGE, Susan Percy IVY, Elise KOHN, Jung-Min LEE
  • Salts of IJAK inhibitors and methods of using the same
    Patent number: 11149029
    Abstract: The present disclosure relates to salts of compounds of Formula (I) prepared as a xinafoate (1-hydroxy-2-naphthoate) salt (Formula (Ia)), pharmaceutically acceptable compositions comprising same and methods of using the same.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: October 19, 2021
    Assignee: AstraZeneca AB
    Inventors: Anna Matilda Angelica Pettersen, James McCabe, Carl-Johan Aurell
  • Synthesis of Mcl-1 inhibitor
    Patent number: 11149024
    Abstract: Disclosed are intermediates and methods of synthesizing Compound 1.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 19, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Craig Robert Stewart, Simon Hardy, Andrew Stark, Alexander Hird, Qing Ye, Xiaolan Zheng, Cati Ferrar, Jan Koek, Debasis Hazra
  • Amino-triazolopyridine compounds and their use in treating cancer
    Patent number: 11136340
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
  • Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors
    Patent number: 11117874
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: September 14, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Hans Roland Lonn, Stephen Connolly, Steven Swallow, Staffan PO Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • MCL-1 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20210230184
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 29, 2021
    Applicant: AstraZeneca AB
    Inventors: Alexander HIRD, Matthew BELMONTE, Wenzhan YANG, Paul SECRIST, Daniel ROBBINS, Steven KAZMIRSKI, Dedong WU, Bo PENG, Jeffrey JOHANNES, Michelle LAMB, Qing YE, XiaoLan ZHENG
  • Phenoxyquinazoline compounds and their use in treating cancer
    Patent number: 11053223
    Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation, pharmaceutical compositions containing them and their use in treating KIT mediated diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 6, 2021
    Assignee: AstraZeneca AB
    Inventors: Tudor Grecu, Jason Grant Kettle, Martin John Packer, Stuart Eric Pearson, James Michael Smith